Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (484)	10/16/2003 8:07:43 PM
From: SemiBull	Read Replies (1) \| Respond to of 513

AVANT To Present At Rodman & Renshaw Techvest Healthcare Conference Thursday October 16, 9:00 am ET NEEDHAM, Mass.--(BUSINESS WIRE)--Oct. 16, 2003--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - News) today announced that Dr. Una S. Ryan, President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will present at the 5th Annual Rodman & Renshaw Techvest Healthcare Conference on Wednesday, October 22nd at 2:00 p.m., EDT. The conference is being held October 21-23 in Boston, MA at the Boston Marriott Long Wharf Hotel. A live audio webcast of the presentation will be available online via the Investor Information area of AVANT's web site at avantimmune.com. An archive of the webcast will be available via AVANT's web site for 60 days following the event. A conference agenda will be posted on the Rodman & Renshaw web site at www.rodmanandrenshaw.com. AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a broad portfolio of vaccines addressing a wide range of applications including bacterial and viral diseases, chronic human disease, biodefense and food safety. These include single-dose, oral vaccines that protect against important disease-causing agents and a novel, proprietary vaccine candidate for cholesterol management. AVANT's goal is to demonstrate proof-of-concept for its products before leveraging their value through partnerships. Current collaborations encompass the development of an oral human rotavirus vaccine, vaccines to combat threats of biological warfare, and vaccines addressed to human food safety and animal health. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: avantimmune.com. Contact: AVANT Immunotherapeutics, Inc. President and CEO Una S. Ryan, Ph.D., 781-433-0771 or AVANT Immunotherapeutics, Inc. Chief Financial Officer Avery W. Catlin, 781-433-0771 info@avantimmune.com or For Media: Kureczka/Martin Associates Joan Kureczka, 415-821-2413 jkureczka@aol.com Source: AVANT Immunotherapeutics, Inc.